Acute myeloid leukaemia
RecruitingStudy Comparing Venetoclax and Azacitidine with Standard Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia Patients with NPM1 Mutations Eligible for Intensive Treatment
Study Comparing Venetoclax and Azacitidine with Standard Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia Patients with NPM1 Mutations Eligible for Intensive Treatment
- Disease:Acute myeloid leukaemia
- Substances:AzacitidineCytarabine+4
Germany- Participants:18–64 years · 65+ years
- Substances:Azacitidine
